Vaccines Market Demand and Growth Strategies

Vaccines Market Size and Forecast (2020–2030), Global and Regional Share, Trend, and Growth Opportunity Analysis

Coverage: Type (Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Subunit & Conjugate Vaccines, and Others), Technology [Recombinant Vaccines, mRNA Vaccines, Cell-Based Vaccines, Virus-Like Particles (VLPs), and Others], Application (Human Papillomavirus, Cancer, MMR, DPT, and Others), Route of Administration (Oral, Injectable, and Nasal), Age (Pediatric Vaccine and Adult Vaccine), End User (Healthcare Facilities, Vaccination Programs and Centers, and Others),(and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)

Download Sample PDF Copy @

Type-Based Insights

Based on type, the vaccines market is segmented as live attenuated vaccines, inactivated vaccines, toxoid vaccines, subunit & conjugate vaccines, and others. The live attenuated vaccines segment held the largest market share in 2022. Live attenuated vaccines are very effective vaccines used in the prevention of a variety of diseases, including influenza, chickenpox, measles, polio, and tuberculosis. As per the World Health Organization (WHO) report, there are around a billion cases of seasonal influenza, including 5 million cases of severe illness. Also, it causes around 290,000 to 650,000 respiratory deaths annually. Therefore, live-attenuated influenza vaccine (LAIV) proves advantageous to combat the infection among the population. For example, LAIV can provide upto 90% protection among adults under 65 years of age and upto 40% of adults over 65. The aforementioned factors are responsible for influential segment growth for the forecast period 2022-2030.

Based on application, the vaccines market is segregated into Human Papillomavirus (HPV), cancer, MMR, DPT, and others. The HPV segment held the largest market share in 2022. According to the WHO report, HPV is highly prevalent among women in Sub-Saharan Africa (24%), followed by Latin America and the Caribbean (16%), Eastern Europe (14%), and South-East Asia (14%). Also, 625,600 women and 694,000 men have HPV-related cancer annually globally. Also, in 2020, cervical cancer accounted for 93% of HPV-related cancers among women. Therefore, there is a high demand for HPV vaccines among the population due to rising prevalent cases, as these vaccines protect against genital warts and most cases of cervical cancer. Also, HPV vaccines are highly approved by the US Food and Drug Administration (USFDA). “GARDASIL 9” is one such example of an HPV vaccine approved by the US FDA. The aforementioned factors are responsible for influential segment growth for the forecast period 2022-2030.

Route of Administration-Based Insights

In terms of route of administration, the vaccines market is categorized as oral, nasal, and injectable. The injectable segment held a larger share of the market in 2022. The most common route of vaccine administration is through the injectable route, as administering a vaccine through a subcutaneous or intradermal route may cause local irritation, skin discoloration, inflammation, and many more.

Further, the CDC report reveals that DTaP, DT, HepA, HepB, Hib, HPV, IIV4, RIV4, ccIIV4, IPV*†, MenACWY, MenB, MMR‡ , PCV13, PPSV23*†, RZV, Td, Tdap, TT, VAR† are common vaccines administered through the injectable route of administration. Varied vaccines administered through injectable routes act as a standalone factor responsible for influential segment growth for the forecast period 2022-2030.



About Us:

The Insight Partners is a market research solution and consultation company. Specializing in syndicate market research, our team helps clients in their hunt for revenue pockets in several industries. A team of 250+ research experts is dedicated to offering the most relevant, data-driven, and trustworthy market insights and consultation.

Contact Us:

If you have any queries about this report or if you would like further information, please contact us

The Insight Partners

Phone: +1-646-491-9876

E-mail: [email protected]